Media coverage about Depomed (NASDAQ:DEPO) has trended somewhat positive this week, according to Alpha One Sentiment Analysis. The research firm, a unit of Accern, scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Depomed earned a media sentiment score of 0.22 on Alpha One’s scale. Alpha One also gave news articles about the specialty pharmaceutical company an impact score of 56 out of 100, indicating that recent press coverage is somewhat likely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have effected Alpha One Sentiment’s analysis:
- ETFs with exposure to Depomed, Inc. : June 16, 2017 (finance.yahoo.com)
- Neuropathic Pain Market Research Report | Trends, outlook and Opportunity Analysis 2026 (medgadget.com)
- Depomed, Inc. (DEPO) Receives $18.72 Average Target Price from Analysts (cote-ivoire.com)
- The Depomed Inc (DEPO) Lifted to Sell at ValuEngine (latribunadecanarias.com)
- Today Depomed Inc (DEPO) Stock Reaches 1 Year Low (healthcaremenu.net)
Shares of Depomed (NASDAQ:DEPO) traded down 3.26% during midday trading on Friday, hitting $9.50. 2,137,851 shares of the stock were exchanged. The stock’s 50-day moving average price is $10.64 and its 200 day moving average price is $15.01. Depomed has a one year low of $9.38 and a one year high of $27.02. The stock’s market cap is $592.24 million.
Depomed (NASDAQ:DEPO) last announced its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.18. Depomed had a negative return on equity of 25.33% and a negative net margin of 21.41%. The company had revenue of $95 million for the quarter, compared to the consensus estimate of $99.48 million. During the same quarter in the prior year, the company earned $0.04 EPS. The company’s revenue for the quarter was down 9.2% on a year-over-year basis. On average, analysts anticipate that Depomed will post $0.64 earnings per share for the current year.
Several analysts recently commented on the stock. Royal Bank of Canada reiterated a “hold” rating and issued a $13.00 price objective on shares of Depomed in a research note on Tuesday. ValuEngine upgraded shares of Depomed from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Mizuho reduced their price objective on shares of Depomed from $13.00 to $11.00 and set a “neutral” rating for the company in a research note on Thursday, May 25th. Cantor Fitzgerald set a $14.00 price objective on shares of Depomed and gave the company a “hold” rating in a research note on Monday, May 15th. Finally, Piper Jaffray Companies upgraded shares of Depomed from an “underweight” rating to a “neutral” rating and reduced their price objective for the company from $11.00 to $10.00 in a research note on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $16.83.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Likely to Impact Depomed (DEPO) Share Price” was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/06/16/depomed-depo-receives-daily-coverage-optimism-score-of-0-22-updated.html.
In related news, insider Arthur J. Higgins acquired 15,000 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were bought at an average price of $9.92 per share, for a total transaction of $148,800.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 5.12% of the company’s stock.
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.